Straumann relocates part of it abroad: 250 jobs in Villeret at risk

Post on: 09.06.2025

The group Straumann, a Swiss giant in the Dental implantology, has announced a strategic turning point that could have significant consequences on employment in Switzerland. The The Basel-based company plans to relocate part of its production to China, a decision that could lead to the elimination of around 250 jobs at its plant in Villeret, Bernese Jura.

Gradual relocation to conquer the Chinese market

The decision is part of an international expansion strategy that focuses decisively on China, a market that already today it represents more than 15% of the group's global turnover. According to what has been communicated by the company's top management, local production is egrave; considered a key element to participate effectively in the procurement, fostering long-term growth and ensuring a stable presence in a strategic area.

The transfer will be carried out gradually and will involve in particular, products destined for China, which will be manufactured on the new Shanghai campus, recently authorized.

The Villeret plant reinvents itself: investments of 60 to 80 million

Despite the employment impact, the company confirms its willà to strengthen Swiss production, announcing an investment plan of 60 to 80 million francs over the next five years for the modernization of the Villeret plant. The site will specialize more and more; in high value-added items and will be The subject of an important technological development, aimed at maintaining high quality standards and distinctive skills.

In the last seven years, Villeret has experienced a Notable expansion: the Organic è increased from approximately 550 to over 1,000 employees, demonstrating the central role of the site in the Group's global production strategy.

Global growth and stability long-term

Founded in 1954, Straumann is now the world's leading manufacturer of dental implants, surgical instruments, biomaterials and tissue regeneration solutions. Its products are used in more than 100 years. of 100 countries and the Company cooperates with universities, research centers and dental clinics around the world. With more than 12,000 employees globally, including 1,800 in Switzerland alone, the company employs more than 12,000 people in Switzerland. is one of the pillars of the Swiss medical and technological sector.

L Company è listed on the Swiss Stock Exchange since 1998. Shares currently stand at around 106 francs, down 6% year-to-date and down 10% year-on-year. However, considering the five-year horizon, the stock still recorded a growth of 32%.

A strategic move that raises questions

While on the one hand the decision to relocate part of production is presented as a necessary move to strengthen competitiveness; in the Asian market, from On the other hand, the social repercussions in Switzerland do not go unnoticed. The possible loss of 250 jobs in the Bernese Jura could fuel a more important debate. Broad on the balance between globalization, sustainability, sustainability, social and local labour protection.

In the coming months, the Attention will be bet on the evolution of the relocation plan and on the accompanying and redevelopment tools that the company metterà in the field for the employees involved.